Companies Cryptocurrencies
IGM Biosciences Inc
IGM Biosciences Inc
Exchange: NasdaqGS
IPO Date: 18/09/2019
CEO: Mr. Fred Schwarzer
Biotechnology Healthcare 🔗
  • IGMS
  • 25.8
  • 1097186304
    market cap
  • 0.07999992
If you bought

shares of IGM Biosciences Inc (IGMS) on
You would have made
Old Price $12 Current Price $12

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 54 full-time employees. The company has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The firm is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).

Address: 325 E Middlefield Rd Mountain View CALIFORNIA 94043

Stay updated.